|
Fibromyalgia Clinical Trials
Duloxetine in the Treatment of
Fibromyalgia Clinical Trial
Study
Shows Promise of Possible New Treatment for Fibromyalgia
While the Food and Drug Administration (FDA) has not yet
approved any treatment protocol for Fibromyalgia, a
preliminary study indicates that the serotonin and
norepinephrine reuptake inhibitor Duloxetine is effective
for the treatment of fibromyalgia -- with or without major
depressive disorder.
Fibromyalgia is a complicated disease that doesn't stem
from a single cause (etiology). This inability to pinpoint
exactly what causes fibromyalgia makes it difficult to
determine effective therapy for the illness.
A report in the September issue of
Arthritis & Rheumatism tells that the results of
one of the largest randomized clinical trials to date, and
the only trial to evaluate the impact of comorbid major
depressive disorder on treatment response, suggests "that
duloxetine improves pain and tenderness, the hallmark
characteristics of fibromyalgia." Lead author Lesley M.
Arnold, MD from the Duloxetine Fibromyalgia Trial Group
further says that "[t]he effect of duloxetine on the
reduction of pain appears to be independent of its effect on
mood."
Additional information on this study and the report can
be found at the
Medscape Medical News site.
Related Fibromyalgia Clinical Trials:
Biofeedback
Gabapentin
September 2004
Page Copyright © 2005 Pamela Rice Hahn
All Rights Reserved |
